KalVista Pharmaceuticals (KALV) Earnings Call Presentation

Sebetralstat Overview - Sebetralstat, if approved, is poised to be the first oral on-demand treatment for Hereditary Angioedema (HAE), potentially transforming the global treatment landscape[20, 22] - Clinical data shows the safety profile of Sebetralstat is no different from placebo, with robust efficacy demonstrated across all attack types, severities, and locations[18, 129] - The median time to beginning of symptom relief was 161 hours for 300 mg and 179 hours for 600 mg of sebetralstat, compared to 672 hours for placebo in Phase III trials[67] - In an open-label extension study, the median time to treatment was 10 minutes overall, 20 minutes for abdominal attacks, and 115 minutes for laryngeal attacks[72] Market Opportunity - The current global HAE market is valued at $13 billion, with a $3 billion global on-demand opportunity[23] - The on-demand market is projected to increase by 70%, driving the global sales to over $4 billion by 2030[89] - In the U S, approximately 84,000 on-demand doses are utilized, with 70% of attacks treated with Firazyr or icatibant[98, 99] Commercialization Strategy - KalVista plans to launch Sebetralstat in the US by June 2025, followed by Germany in 2H 2025, and the UK and Japan in 1H 2026[20, 123] - The company anticipates broad payor access, primarily through commercial coverage, with pricing comparable to existing branded therapies, ranging from $11,000 to $16,000 per attack[17, 110] - KalVista is targeting the top 1,000 HCPs and is focusing on patients currently using Firazyr and icatibant to drive early demand and accelerate adoption[126]